Decades of dedicated research into RNA modulation, sophisticated chemical alterations, and targeted delivery mechanisms are fundamentally transforming the scope and future trajectory of programmable genetic therapies.
In a recent publication within the esteemed journal Cell Reports Medicine, a collective of researchers meticulously examined the operational principles, chemical enhancements, administration strategies, clinical evolution, and prospective applications of therapeutic oligonucleotides as innovative genetic pharmaceuticals.
Details of the Breakthrough in Oligonucleotide Therapies
Currently, twenty-one therapeutic oligonucleotides have achieved regulatory approval, though two were subsequently withdrawn, marking a significant paradigm shift in the treatment of genetic ailments. These therapeutic oligonucleotides comprise chemically modified nucleic acid molecules engineered to influence gene expression by interacting with specific RNA sequences. Antisense oligonucleotides (ASOs) are capable of inducing RNA degradation or altering the processing of pre-messenger RNA (pre-mRNA), while small interfering RNAs (siRNAs) facilitate the breakdown of targeted messenger RNA (mRNA). Progress in chemical modification and delivery has substantially enhanced their stability, effectiveness, longevity, and specificity of action. However, significant hurdles persist, particularly in achieving delivery beyond the liver, ensuring safety, and developing personalized treatment protocols.
Therapeutic oligonucleotides typically consist of a phosphate backbone, a ribose sugar, and nitrogenous bases. ASOs are generally single-stranded molecules, ranging from 15 to 30 nucleotides in length. Some ASOs recruit ribonuclease H (RNase H) to degrade specific RNA targets. Others function as steric blockers by binding to pre-mRNA, thereby modifying splicing to restore protein production or switch protein isoforms. siRNAs, approximately 21 nucleotides long, operate via the RNA-induced silencing complex (RISC), where their guide strand directs Argonaute 2 (Ago2) to complementary mRNA, prompting its cleavage. MicroRNA (miRNA) mimics utilize similar RNA interference mechanisms but can modulate multiple targets. Small activating RNAs (saRNAs) and antagomirs are also being explored for their potential to augment gene expression.
Chemical modification has been pivotal to clinical advancements, as unmodified DNA and RNA are rapidly degraded and cleared. Phosphorothioate (PS) backbone modifications bolster nuclease resistance, protein binding, and tissue uptake. Ribose modifications, such as 2′-methoxyethyl (2′-MOE), locked nucleic acid (LNA), and constrained ethyl (cEt), can amplify stability and target binding. Nevertheless, excessive use of LNA and cEt has been linked to liver toxicity. Phosphorodiamidate morpholino oligomers (PMOs) exhibit high nuclease resistance and neutrality but can suffer from poor systemic bioavailability due to the absence of a PS backbone. For siRNAs, 2′-O-methyl (2′-OMe), 2′-fluoro (2′-F), and extended nucleic acid (exNA) modifications improve stability and activity, with specific patterns designed to maintain RISC function.
Oligonucleotides are relatively large and possess a negative charge, impeding their easy passage across cell membranes. Successful therapy necessitates protection from degradation, evasion of clearance, access to target tissues, cellular absorption, and escape from lysosomes. Local administration can circumvent certain barriers, as seen in approved or previously approved therapies involving intravitreal delivery to the eye and intrathecal administration to the central nervous system (CNS). Systemic administration is employed when circulatory distribution can reach the target tissue. Subcutaneous administration is widely favored due to its less invasive nature and lack of requirement for specialized personnel.
Delivery systems encompass lipids, polymers, inorganic materials, peptides, and biologically derived carriers. Lipid-based systems are well-advanced clinically; for instance, patisiran, an siRNA therapy encapsulated in a lipid nanoparticle, gained approval for transthyretin-mediated amyloidosis. Ligand conjugation offers selective delivery. N-acetylgalactosamine (GalNAc) binds to the asialoglycoprotein receptor (ASGPR), which is highly expressed on hepatocytes, making GalNAc conjugates effective for liver delivery. Antibody-oligonucleotide conjugates have progressed to clinical trials for muscle delivery, while oligonucleotide-based strategies for crossing the blood-brain barrier remain in preclinical stages. Lipid conjugates are under investigation for applications in the liver, muscle, CNS, placenta, and skin. Peptide-based approaches have demonstrated promise for cellular uptake and endosomal escape, although toxicity issues have hindered some clinical developments.
Artificial intelligence (AI) is poised to assist in target selection, sequence design, chemical modification, delivery optimization, manufacturing, and safety evaluation. This review underscores that AI will complement, not replace, empirical testing, and its effectiveness will hinge on extensive, high-quality datasets, including data from unsuccessful or unsafe treatments. Therapeutic oligonucleotides are also progressing towards personalized medicine. Milasen, developed for a single patient with CLN7 Batten disease, served as a proof of concept, and since then, over 40 different ASOs have been created for more than 80 patients. These personalized approaches demand accelerated development, streamlined regulatory processes, enhanced infrastructure, continuous monitoring, and robust data sharing.
The application of these therapies is expanding beyond rare conditions. Inclisiran has established its role in prevalent hypercholesterolemia, and additional ASOs and siRNAs targeting PCSK9, ANGPTL3, and apolipoprotein C3 (APOC3) are under development. The lipoprotein(a)-reducing ASO, pelacarsen, is being evaluated in patients receiving inclisiran. Continued expansion relies on validating effective targets and overcoming delivery obstacles to reach a wider array of tissues.
The journey of therapeutic oligonucleotides from theoretical concept to a recognized class of genetic medicines is a testament to the profound progress in chemistry, delivery methods, and our comprehension of RNA biology. Approved ASOs and RNA interference therapies now offer solutions for both rare and common ailments, while personalized treatments exemplify the remarkable adaptability of programmable genetic interventions. The review highlights that improved extrahepatic delivery, enhanced safety profiles, data integrity, streamlined regulatory frameworks, and rigorous target validation remain paramount. While AI promises to accelerate numerous developmental phases, empirical validation remains indispensable. Ongoing breakthroughs in delivery science and chemical engineering could significantly broaden the range of tissues, diseases, and patient populations benefiting from these transformative therapies.